Core Viewpoint - The company, InnoCare Pharma (02577.HK), has submitted an application to the China Securities Regulatory Commission to convert 373,841,270 domestic unlisted shares into H-shares, aiming for full circulation of H-shares [1] Summary by Relevant Sections Company Actions - InnoCare Pharma has applied for the conversion of 373,841,270 domestic unlisted shares into H-shares, which will allow these shares to be traded on the Hong Kong Stock Exchange after obtaining necessary regulatory approvals [1] - The total share capital of the company is 894,400,653 shares, with H-shares totaling 504,841,187 shares, representing approximately 56.44% of the total share capital [1] Shareholder Communication - Communication with all holders of domestic unlisted shares indicates that 373,841,270 shares, or about 95.97% of the total domestic unlisted shares, support the H-share full circulation application, which accounts for approximately 41.80% of the company's total share capital [1] Post-Conversion Structure - Upon completion of the H-share full circulation, the total number of H-shares will increase to 878,682,457 shares, representing approximately 98.24% of the company's total share capital, while the number of domestic unlisted shares will decrease to 15,718,196 shares, accounting for about 1.76% of the total share capital [1]
英诺赛科(02577.HK))拟实施H股全流通计划